IDH1 and cholangiocarcinoma: The inhibition of the IDH1 mutation through its inhibitor ivosidenib represents a recent breakthrough in second-line therapy for cholangiocarcinoma, dramatically improved median PFS (2.7 months vs 1.4 months, HR = 0.37, one-sided p < 0.0001) compared with placebo (23).